Bousquet J., Pfaar O., Togias A. et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019Devey M.E., Wilson D.V., Wheeler A.W. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin. Allergy. 1976;6:227-36.Flicker, S., Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int. Arch. Allergy Immunol. 2003; 132: 13-24.Garcia B.E., Sanz M.L., Dieguez I., de las Marinas M.D., Oehling A. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. J. Investig. Allergol. Clin. Immunol. 1993; 3: 19-25.Gehlhar K., Schlaak M., Becker W.M., Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin. Exp. Allergy. 199)9; 29: 497-506.Gomez E., Fernandez T.D., Dona I., Rondon C., Campo P., Gomez F. et al. Initial immunological changes as predictors for House Dust Mite immunotherapy response. Clin. Exp. Allergy. 2015; 45: 1542-1553.Linneberg A., Dam Petersen K., Hahn-Pedersen J., Hammerby E., Serup-Hansen N., Boxall N. Burden of allergic respiratory disease: a systematic review. Clin. Mol. Allergy. 2016; 14:12.Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006; 61: 151-165.Moverare R., Elfman L., Vesterinen E., Metso T., Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002; 57: 423-430.Nelson H.S., Nolte H., Creticos P., Maloney J., Wu J.M., Bernstein D.I. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J. Allergy Clin. Immunol. 2011; 127: 72-80.Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011; 66: 740-752.Roberts G., Pfaar O., Akdis C.A., et al. EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018; 73: 765-798.Shamji M.H., Kappen J.H., Akdis M. et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017.Wachholz, P.A., Durham S.R. Mechanisms of immunotherapy: IgG revisited. Curr. Opin. Allergy Clin. Immunol. 2004; 4: 313-318.